Meropenem

Meropenem is a broad-spectrum antibiotic belonging to the carbapenem class of beta-lactam antibacterial medicines. It works by inhibiting bacterial cell-wall synthesis, binding to penicillin-binding proteins that bacteria need to maintain their structural integrity. This action kills susceptible bacteria and helps control infections caused by a range of Gram-positive and Gram-negative organisms, including bacteria responsible for serious infections in hospital settings. Meropenem is administered intravenously, either as an injection or infusion prepared according to the product instructions. It is used when the suspected or confirmed bacterial infection requires treatment with this antibiotic and the causative organisms are expected to be susceptible. Approved clinical applications in the United States include complicated skin and skin-structure infections, complicated intra-abdominal infections, and bacterial meningitis in eligible paediatric patients. Other uses depend on local approvals, clinical guidelines, and susceptibility information. Meropenem does not treat viral infections such as influenza or the common cold. Appropriate selection, dosing, and duration are important to achieve treatment success while reducing the development of antimicrobial resistance. Kidney function, infection severity, microbiology results, allergies, and concurrent medicines should be considered before and during therapy.

Meropenem was developed as a synthetic carbapenem antibiotic for treating serious infections caused by susceptible bacteria. Its antibacterial activity results from inhibition of bacterial cell-wall synthesis, and its spectrum includes many clinically important Gram-negative and anaerobic organisms. Meropenem received initial approval from the United States Food and Drug Administration (FDA) in 1996. Its use has subsequently been established through clinical trials and extensive clinical experience. Regulatory approvals and authorised indications vary by country and product formulation. In the United States, approved indications include complicated skin and skin-structure infections, complicated intra-abdominal infections, and bacterial meningitis in eligible paediatric patients. Clinical studies supporting its use have evaluated these infections in defined patient populations. Prescribers should consult the current locally approved prescribing information for applicable indications, age restrictions, dosing recommendations, and safety requirements.

Meropenem is used to treat serious bacterial infections caused by susceptible organisms. Depending on the product approval and local clinical guidelines, indications include complicated skin and skin-structure infections, complicated intra-abdominal infections, and bacterial meningitis in eligible paediatric patients. In hospital practice, it may also be selected for certain cases of severe pneumonia, complicated urinary tract infection, bloodstream infection, intra-abdominal sepsis, or febrile neutropenia when clinical assessment and local guidelines support its use. Some of these applications depend on regional approvals and treatment protocols. Meropenem may be used alone or alongside other antimicrobial medicines when broader coverage or treatment of a mixed infection is required. It is not reliably active against every resistant bacterium, including methicillin-resistant Staphylococcus aureus (MRSA), and resistance among Gram-negative organisms can limit its effectiveness. Cultures and antimicrobial susceptibility testing should guide treatment whenever feasible. Meropenem should be reserved for infections in which its expected benefits justify its use and should not be used for viral illnesses.

Meropenem is administered intravenously by a healthcare professional, generally as an infusion over a period specified in the product information; some approved regimens permit intravenous bolus administration. Adult dosing depends on the infection, its severity, the susceptibility of the causative organism, and the patient's kidney function. Common adult regimens include 500 mg every eight hours for certain skin and skin-structure infections and 1 g every eight hours for complicated intra-abdominal infections under the US prescribing information. Other infections may require different regimens according to the applicable label and clinical circumstances. Kidney-function-based dose or interval adjustment is generally necessary in patients with reduced renal function. Paediatric doses are calculated according to body weight, age, infection type, and the applicable product label. Treatment duration depends on clinical response, infection site, microbiological findings, and source control where needed. The intravenous solution must be prepared, handled, and administered according to product-specific instructions. Patients should not self-administer or alter the dose, interval, or duration without medical supervision.

Common or reported side effects of meropenem include diarrhoea, nausea, vomiting, headache, rash, injection-site reactions, and inflammation or discomfort around the infusion site. Some patients may experience changes in liver enzyme levels or blood-cell counts during treatment. The likelihood and severity of side effects depend on the patient's condition, dose, duration of therapy, and other medicines being used. Gastrointestinal symptoms and local administration reactions may be manageable, but persistent or worsening symptoms should be reported to a healthcare professional. Diarrhoea that is severe, persistent, or associated with abdominal pain or fever requires assessment because antibiotic-associated colitis can occur. Laboratory monitoring may be appropriate during prolonged treatment or in patients with significant underlying illness.

Serious adverse effects of meropenem can include severe allergic reactions, serious skin reactions, seizures, and antibiotic-associated colitis. Seizure risk may be increased in patients with central nervous system disorders, a history of seizures, impaired kidney function, or excessive drug exposure. Severe hypersensitivity reactions can occur, particularly in people with a history of serious allergy to beta-lactam antibiotics. Severe or persistent diarrhoea may indicate Clostridioides difficile-associated disease and requires prompt medical evaluation. Changes in blood-cell counts, liver function, and other laboratory parameters may occur. Meropenem can also interact significantly with valproic acid or valproate, potentially reducing valproate concentrations and increasing the risk of breakthrough seizures. Treatment should be reviewed promptly if a serious reaction is suspected. Meropenem should not be used in patients with a known serious hypersensitivity to the medicine or its ingredients, and the relevant product information should be checked for specific contraindications and warnings.

Before treatment, clinicians should assess any history of allergy to meropenem, penicillins, cephalosporins, or other beta-lactam antibiotics. Kidney function should be reviewed because reduced clearance can lead to increased drug exposure and may require dose adjustment. A history of seizures, neurological disease, gastrointestinal disease, or previous antibiotic-associated colitis should also be considered. Pregnancy and breastfeeding require an individual assessment of potential benefits and risks. Meropenem may interact significantly with valproic acid or valproate, and concurrent use is generally avoided because meropenem can substantially lower valproate concentrations. Probenecid can increase meropenem exposure and is generally not recommended for concurrent use. Other medicines and laboratory results should be reviewed as clinically appropriate. Microbiology results and local resistance patterns are important in selecting therapy. Unnecessary or prolonged use can contribute to antimicrobial resistance and disruption of normal intestinal bacteria. Treatment should be reviewed when culture and susceptibility results become available.

Confirm the suspected infection, relevant culture results, local susceptibility patterns, and indication-specific dosing before initiating meropenem. Obtain appropriate microbiological samples before the first dose when this can be done without delaying urgent treatment. Assess renal function and review the dosing schedule regularly, particularly in older adults, critically ill patients, and those whose kidney function is changing. Check the medication history carefully for valproate or valproic acid and other clinically relevant interactions. Ensure that reconstitution, dilution, infusion duration, compatibility, storage, and beyond-use instructions follow the specific product information. Monitor clinical response, temperature, infection markers, renal function, and blood counts or liver tests when indicated by the patient's condition and treatment duration. Reassess the need for meropenem when microbiology results become available and narrow therapy where an effective, more targeted antibiotic is appropriate. Provide counselling about allergic symptoms and severe or persistent diarrhoea. Document the intended treatment duration and review the regimen regularly to support effective therapy and antimicrobial stewardship.